Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:71-76
Published online before print October 28, 2004, doi: 10.1161/01.ATV.0000148863.24445.b4
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
25/1/71    most recent
01.ATV.0000148863.24445.b4v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Presta, M.
Right arrow Articles by Ribatti, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Presta, M.
Right arrow Articles by Ribatti, D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Heparin
Right arrow Angiogenesis
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:71.)
© 2005 American Heart Association, Inc.

Vascular Biology

Antiangiogenic Activity of Semisynthetic Biotechnological Heparins

Low-Molecular-Weight-Sulfated Escherichia coli K5 Polysaccharide Derivatives as Fibroblast Growth Factor Antagonists

Marco Presta; Pasqua Oreste; Giorgio Zoppetti; Mirella Belleri; Elena Tanghetti; Daria Leali; Chiara Urbinati; Antonella Bugatti; Roberto Ronca; Stefania Nicoli; Emanuela Moroni; Helena Stabile; Maura Camozzi; German Andrés Hernandez; Stefania Mitola; Patrizia Dell’Era; Marco Rusnati; Domenico Ribatti

From the Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology (M.P., M.B., E.T., D.L., C.U., A.B., R.R., S.N., E.M., H.S., M.C., G.A.H, S.M., P.D., M.R.), School of Medicine, University of Brescia; Glycores 2000 Srl (P.O., G.Z.), Milano; and the Department of Human Anatomy and Histology (D.R.), University of Bari, Italy.

Correspondence to Marco Presta, General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, viale Europa 11, 25123 Brescia, Italy. E-mail presta{at}med.unibs.it


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Objective— Low-molecular-weight heparin (LMWH) exerts antitumor activity in clinical trials. The K5 polysaccharide from Escherichia coli has the same structure as the heparin precursor. Chemical and enzymatic modifications of K5 polysaccharide lead to the production of biotechnological heparin-like compounds. We investigated the fibroblast growth factor-2 (FGF2) antagonist and antiangiogenic activity of a series of LMW N,O-sulfated K5 derivatives.

Methods and Results— Surface plasmon resonance analysis showed that LMW-K5 derivatives bind FGF2, thus inhibiting its interaction with heparin immobilized to a BIAcore sensor chip. Interaction of FGF2 with tyrosine-kinase receptors (FGFRs), heparan sulfate proteoglycans (HSPGs), and {alpha}vß3 integrin is required for biological response in endothelial cells. Similar to LMWH, LMW-K5 derivatives abrogate the formation of HSPG/FGF2/FGFR ternary complexes by preventing FGF2-mediated attachment of FGFR1-overexpressing cells to HSPG-bearing cells and inhibit FGF2-mediated endothelial cell proliferation. However, LMW-K5 derivatives, but not LMWH, also inhibit FGF2/{alpha}vß3 integrin interaction and consequent FGF2-mediated endothelial cell sprouting in vitro and angiogenesis in vivo in the chick embryo chorioallantoic membrane.

Conclusions— LMW N,O-sulfated K5 derivatives affect both HSPG/FGF2/FGFR and FGF2/{alpha}vß3 interactions and are endowed with FGF2 antagonist and antiangiogenic activity. These compounds may provide the basis for the design of novel LMW heparin-like angiostatic compounds.

Low-molecular-weight compounds from a N,O-sulfated derivative of Escherichia coli K5 polysaccharide bind fibroblast growth factor-2, thus inhibiting its receptor interactions. They also inhibit endothelial cell proliferation and sprouting and angiogenesis in vivo. These semisynthetic biotechnological heparin-like compounds may provide the basis for the design of novel angiostatic molecules.


Key Words: angiogenesis • endothelium • FGF • heparin • integrin


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Heparin is a natural sulfated glycosaminoglycan (GAG) used as anticoagulant and antithrombotic drug.1 Heparin is heterogeneous in size: unfractionated heparin (UFH) shows an average molecular weight (MW) of 13 000 to 15 000 with chains ranging from 5000 to 30 000. Heparin structure is largely accounted for by regular trisulfated disaccharide sequences made of alternating {alpha}-1,4-linked residues of 2-O-sulfated L-iduronic acid (IdoA) and N,6-disulfated D-glucosamine (GlcN). These sequences are occasionally interrupted by nonsulfated uronic acids and undersulfated hexosamines,1 including 3-O–sulfated GlcNs present in the antithrombin III-binding pentasaccharidic sequence relevant for anticoagulant activity.2

Heparin binds to a variety of biologically active polypeptides.3 This capacity may be exploited to design heparin-derived drugs for pharmacological interventions in a variety of pathologic conditions besides coagulation and thrombosis, including neoplasia. Actually, heparins show antitumor activity in clinical trials4–6 without affecting the incidence of thrombotic and bleeding complications, thus suggesting a direct effect of heparins on cancer progression. Indeed, heparins may inhibit malignant growth by different mechanisms,6,7 including the suppression of tumor neovascularization after interaction with angiogenic growth factors (reviewed in Presta et al8).

Fibroblast growth factor-2 (FGF2) is a major heparin-binding angiogenic growth factor and a possible target for antiangiogenic therapies.9 FGF2 exerts its activity on endothelial cells by interacting with tyrosine-kinase receptors (FGFRs)10 and heparan sulfate proteoglycans (HSPGs),11 thus forming HSPG/FGF2/FGFR ternary complexes.12 Heparin competes with HSPGs and FGFRs for the binding to FGF2.13 Therefore, synthetic molecules and chemically modified heparins able to interfere with HSPG/FGF2/FGFR interaction may act as angiogenesis inhibitors (reviewed in Presta et al8). Also, FGF2 binds to endothelial {alpha}vß3 integrin, and this interaction is required for biological response.14,15 Accordingly, FGF2/{alpha}vß3 integrin interaction antagonists are endowed with antiangiogenic activity in vitro and in vivo.16

The capsular K5 polysaccharide from Escherichia coli has the same structure [-> 4)-ß-D-GlcA-(1 -> 4)-{alpha}-D-GlcNAc-1(1 ->]n as the heparin precursor N-acetyl heparosan17 in which GlcA is glucuronic acid and GlcNAc is N-acetyl-glucosamine. Chemical and enzymatic modifications of the K5 polysaccharide lead to the synthesis of heparin-like compounds18 endowed with different biological properties, including anticoagulant/antithrombotic,19,20 antineoplastic,21 and anti-AIDS22 activities. Recently, we demonstrated that a highly N,O–sulfated K5 derivative [K5-N,OS(H)] binds FGF2 with high affinity and exerts a potent antiangiogenic activity.23 Thus, K5-N,OS(H) may provide the basis for the design of novel angiostatic compounds with therapeutic implications in different angiogenesis-dependent diseases, including cancer.

Low-molecular-weight heparins (LMWHs) are obtained by chemical or enzymatic depolymerization of UFH. LMWH has favorable pharmacokinetics compared with conventional heparin.24,25 Relevant to the use of heparins in cancer therapy, LMWH prolongs disease-free survival time and reduces death rate in cancer patients.6 In this study, we synthesized a series of LMW derivatives of K5-N,OS(H) that were assessed for their FGF2 antagonist activity in vitro and angiostatic capacity in vivo.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Materials
Recombinant FGF2 was from Pharmacia-Upjohn (Milan, Italy). UFH (average MW=13 700; sulfate/carboxyl ratio [SO3–/COO–]=2.14) was obtained from unfractionated beef mucosa sodium heparin (Laboratori Derivati Organici, Milan, Italy). LMWH (average MW=5000; SO3–/COO–=2.13) was provided by C. Pisano (Sigma-Tau, Pomezia, Italy). K5 polysaccharide (average MW=30 000) was prepared as described.23 Cyclo(-Arg-Gly-Asp-D-Phe-Val) peptide [c(RGDfV)] and cyclo(-Arg-Ala-Asp-D-Phe-Val) peptide [c(RADfV)] were from Bachem AG.

LMW-K5 Derivatives
Derivatives were generated by nitrous acid depolymerization and subsequent reduction from a single batch of K5-N,OS(H)23 (for details, please see the online Methods, available at http://atvb.ahajournals.org.). 13C-NMR spectrum analysis, SO3–/COO– analysis, and MW determinations of the different samples were performed as described.23

BIAcore Binding Assay
Biotinilated UFH was immobilized (6.0 fmol/mm2) to a streptavidin-activated sensor chip (BIAcore Inc, Piscataway, NJ). Increasing concentrations of FGF2 in 10 mmol/L HEPES, 150 mmol/L NaCl, 3.4 mmol/L EDTA, 0.005% surfactant P20 (pH 7.4), were then injected over the heparin-coated surface for 4 minutes and washed until dissociation was observed. The signal was expressed as resonance units. Also, FGF2 (160 nmol/L) was injected over the heparin-coated sensor chip in the presence of increasing GAG concentrations. A streptavidin-activated sensor chip was used for blank subtraction.

FGF2-Mediated Cell-Cell Adhesion Assay
Chinese hamster ovary (CHO)-K1 cells were seeded at 52 000 cells per cm2 in 24-well plates. After 24 hours, cell monolayers were fixed with 3% glutaraldehyde in PBS. Then, A745 CHO flg-1A cells, generated by transfection of GAG-deficient A745 CHO cells26 with the IIIc variant of murine FGFR1 cDNA,27 were added at 52 000 cells per cm2 to CHO-K1 monolayers in serum-free medium plus 10 mmol/L EDTA with no addition or with 30 ng/mL FGF2 in the presence of increasing concentrations of the different GAGs. After 2 hours at 37°C, cells bound to the monolayer were counted under an inverted microscope.23

Cell Proliferation Assay
Bovine endothelial GM7373 cells (Human Genetic Mutual Cell Repository, Camden, NJ) were seeded at 70 000 cells per cm2 in 24-well plates. After overnight incubation in Eagle’s minimal essential medium containing 10% FCS, cells were incubated in medium containing 0.4% FCS and 10 ng/mL FGF2. After 8 hours, increasing concentrations of GAGs were added to cell cultures without changing the medium. Sixteen hours thereafter, cells were trypsinized and counted.23

Fibrin Gel Sprouting Assays
FGF2-transfected murine endothelial FGF2-T-MAE cell aggregates28 were prepared on agarose-coated plates and seeded within fibrin gel.23 Then, culture medium with or without K5 derivatives (100 µg/mL) or cyclic pentapeptides (60 µmol/L) was added. Formation of radially growing cell sprouts was quantified after 24 hours by image analysis of the digitized images using the Image-Pro Plus software (Media Cybernetics). Freshly prepared rat aorta rings29 were cultured in fibrin gel for 7 days in the presence of the different antagonists. Rings were examined daily and neovessels counted under an inverted microscope.

Cell Adhesion Assay
Polystyrene nontissue culture 96-well plates were coated with 20 µg/mL FGF2, vitronectin, or fibronectin as described.14 Next, 50 000 GM7373 cells were seeded in the absence or presence of the antagonist. After 2 hours at 37°C, adherent cells were quantified by methylene blue/Azur II staining.14

Chick Embryo Chorioallantoic Membrane Assay
At day 8 of incubation, sterilized gelatin sponges (1 mm3; Gelfoam, Upjohn Co) adsorbed with the K5-derivative dissolved in 3 µL of PBS (50 µg/embryo) were implanted on the top of growing chorioallantoic membranes (CAMs).23 Sponges containing vehicle alone were used as negative controls. CAMs were examined under a stereomicroscope until day 12, and blood vessels around the sponges were counted (10 eggs per group).


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
Production of LMW-K5 Derivatives
K5 derivatives with reduced size were prepared by controlled chemical depolymerization of K5-N,OS(H) (SO3–/COO–=3.87; average MW of 20 700). Three LMW compounds [LMW-K5(A), LMW-K5(B), and LMW-K5(C) with MW equal to 6000, 5000, and 4200, respectively] and 1 derivative with an intermediate MW of 11 000 (IMW-K5) were obtained. As for K5-N,OS(H),23 the compounds carry 1 N-sulfated group and 1 6-O–sulfated group in all GlcN residues, with 70% of their sequence being represented by GlcA2,3SO3–-GlcNSO3–,6SO3– disaccharide units (Figure I, available online at http://atvb.ahajournals.org).

Binding of LMW-K5 Derivatives to FGF2
LMW-K5 derivatives were evaluated for the capacity to interact with FGF2 by preventing its binding to biotinilated heparin immobilized onto a streptavidin-activated BIAcore sensor chip. FGF2 binds to the heparin-coated sensor chip, but not to the streptavidin-activated sensor chip, in a dose-dependent manner (Figure II, available online at http://atvb.ahajournals.org). An association rate constant equal to 9.0x103 M–1 s–1 and a dissociation rate constant equal to 3.8x10–4 s–1 characterize the interaction that occurs with high affinity (Kd=42.5 nmol/L), consistent with previous determinations.30,31

On this basis, increasing concentrations of LMW-K5 derivatives or UFH were preincubated with FGF2 and then injected onto the heparin-coated sensor chip. All the compounds caused a dose-dependent inhibition of FGF2/heparin interaction (Figure 1). LMW-K5(A), LMW-K5(B), and LMW-K5(C) showed a similar potency (ID50=100 to 120 nmol/L), 4 to 5x lower than that observed for K5-N,OS(H) and IMW-K5. These differences were, however, abolished when the concentration of the different compounds was expressed on a weight basis (ID50 values ranging from 0.3 µg/mL to 0.6 µg/mL). When compared with K5 derivatives, UFH (MW of 13 700) appeared to be a more active competitor (ID50=6.0 nmol/L, corresponding to 0.08 µg/mL). Finally, a LMWH preparation (MW of 5000) inhibited the binding of FGF2 to immobilized heparin with a similar potency (ID50=20 nmol/L, corresponding to 0.1 µg/mL; Figure 1). No effect was instead exerted by unmodified K5 (not shown).



View larger version (32K):
[in this window]
[in a new window]
  		Figure 1. Surface plasmon resonance analysis of LMW-K5 derivative/FGF2 interaction. FGF2 (160 nmol/L) was injected over a heparin-coated BIAcore sensor chip in the presence of increasing concentrations of the different GAGs. The response was recorded at the end of injection and plotted as a function of the GAG concentration.

Effect of LMW-K5 Derivatives on HSPG/FGF2/FGFR Ternary Complex
FGF2 mediates cell-cell attachment by linking FGFRs and HSPGs on neighboring cells through the formation of HSPG/FGF2/FGFR ternary complexes.32 Indeed, HSPG-deficient FGFR1-transfected A745-CHO flg-1A cells adhere to a monolayer of HSPG-bearing CHO-K1 cells when incubated in the presence of 30 ng/mL FGF2 but not in the absence of the growth factor.27 K5-N,OS(H) inhibits FGF2-mediated cell-cell attachment in this model.23

When tested under the same experimental conditions, all the LMW-K5 compounds and IMW-K5 hamper the formation of the HSPG/FGF2/FGFR ternary complex with an activity equal to that shown by the parent compound K5-N,OS(H) and LMWH (ID50=0.3 µg/mL) and only slightly less potent than that exerted by UFH (ID50=0.1 µg/mL). Unmodified K5 was ineffective (Figure 2A).



View larger version (27K):
[in this window]
[in a new window]
  		Figure 2. Effect of LMW-K5 derivatives on FGF2-mediated cell-cell adhesion and endothelial cell proliferation. A, HSPG-deficient FGFR1 transfectants were added to CHO monolayers in the presence of 30 ng/mL FGF2 and increasing concentrations of the different GAGs. After 2 hours at 37°C, adherent cells were counted. B, The different GAGs were tested for the capacity to inhibit FGF2-mediated proliferation in GM7373 cells. Data are expressed as percentage of the proliferation measured in the absence of any competitor. In both A and B, experiments were performed in triplicate and repeated 3x with similar results.

Effect of LMW-K5 Derivatives on Endothelial Cell Proliferation and Sprouting
To evaluate a possible angiosuppressive activity of LMW-K5 derivatives, we evaluated their capacity to affect FGF2-mediated cell proliferation in bovine endothelial GM7373 cells. Similar to heparin and LMWH, LMW-K5 derivatives and IMW-K5 inhibit endothelial cell proliferation (ID50=1 to 3 µg/mL). No inhibition was instead exerted by unmodified K5 (Figure 2B).

The capacity of K5 derivatives to affect angiogenesis was investigated further by an in vitro sprout formation assay. In this assay, FGF2-transfected endothelial FGF2-T-MAE cell aggregates are embedded into a fibrin gel in which they form solid cell sprouts after 1 to 2 days in culture.33 As shown in Figure 3A (see also Figure III, available online at http://atvb.ahajournals.org), K5 derivatives exert a significant inhibitory effect on FGF2-T-MAE cell sprouting, whereas unmodified K5, UFH, and LMWH are ineffective. Also, endothelial cell sprouting was suppressed by the {alpha}vß3 integrin antagonist cyclic pentapeptide c(RGDfV)34 but not by the control peptide c(RADfV; Figure 3A).



View larger version (37K):
[in this window]
[in a new window]
  		Figure 3. Effect of LMW-K5 derivatives on endothelial cell sprouting. A, FGF2-T-MAE cell aggregates were seeded in fibrin gel in the presence of the different GAGs (100 µg/mL) or cyclic peptides (60 µmol/L). After 24 hours, sprouting was evaluated by computerized image analysis. Data are the mean±SEM of 3 experiments in triplicate. B, Rat aorta rings were embedded in fibrin gel in the presence of vehicle or of LMW-K5(A), LMWH (both at 100 µg/mL), or cyclic peptides (60 µmol/L). Neovessels that sprout out of the rings were counted during the next 7 days. Data represent 4 rings per experimental condition. Similar results were obtained in a second independent experiment.

Accordingly, LMW-K5(A) and c(RGDfV), but not LMWH and c(RADfV), inhibit endothelial cell sprouting in an ex vivo assay in which new capillary-like structures originate spontaneously from the endothelium of fibrin-embedded rat aorta rings29 (Figure 3B and Figure III).

Effect of LMW-K5 Derivatives on FGF2/{alpha}vß3 Integrin Interaction
Integrins, including {alpha}vß3, play an important role in angiogenesis.35 Also, FGF2 binds {alpha}vß3, and this interaction is required for endothelial cell response to the growth factor.14–16 The capacity of K5 derivatives to inhibit endothelial cell sprouting similar to the integrin antagonist c(RGDfV) prompted us to assess the possibility that K5 derivatives may affect FGF2/{alpha}vß3 interaction. Endothelial cells adhere and spread on FGF2-coated plastic through FGF2/{alpha}vß3 interaction.14,15 Both K5-N,OS(H) and LMW-K5(C) prevent GM7373 cell adhesion to immobilized FGF2, whereas UFH and LMWH are ineffective (Figure 4). Similar results were obtained with LMW-K5(A) and the integrin antagonist c(RGDfV), whereas control c(RADfV) was ineffective (data not shown). The effect of K5 derivatives on FGF2/{alpha}vß3-mediated endothelial cell adhesion was specific, because K5-N,OS(H) and LMW-K5(C) did not inhibit cell adhesion to the prototypic integrin ligands vitronectin and fibronectin.



View larger version (62K):
[in this window]
[in a new window]
  		Figure 4. Effect of LMW-K5 derivatives on FGF2/{alpha}vß3 interaction. GM7373 cells were seeded on plastic coated with FGF2, fibronectin (FN), or vitronectin (VN) in the absence or presence of UFH, LMWH, K5-N,OS(H), or LMW-K5(C). Adherent cells were counted after 2 hours.

Effect of LMW-K5 Derivatives on Chick Embryo CAM Angiogenesis
Various FGF2 antagonists, including heparin-like compounds and {alpha}vß3 antagonists, exert a significant antiangiogenic activity in the chick embryo CAM.16,23,36,37 When delivered on the top of the CAM through a gelatin sponge implant, all the K5 derivatives inhibited blood vessel growth. This was observed in 70% of the embryos treated with K5-N,OS(H), in 80% of those treated with LMW-K5(A) or LMW-K5(B), and in 90% of the embryos treated with LMW-K5(C). Accordingly, the number of blood vessels surrounding the implants decreased rapidly during incubation with K5-N,OS(H) or with the different LMW-K5 compounds compared with the physiological increase in vascularization observed in vehicle-treated embryos (Figure 5 and Figure III). In agreement with previous observations, unmodified K5 and heparin did not affect CAM neovascularization.23,36,37



View larger version (26K):
[in this window]
[in a new window]
  		Figure 5. Effect of LMW-K5 derivatives on chick embryo CAM vascularization. Gelatin sponges adsorbed with vehicle or K5 derivatives (all at 50 µg per embryo) were implanted on the top of CAMs at day 8. CAMs were examined daily, and blood vessels around the sponges were counted (n=10).


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
Here, a series of LMW-K5 compounds (MW ranging from 6000 to 4200) obtained by controlled chemical depolymerization of a high MW N,O-sulfated K5 derivative23 exert a potent FGF2 antagonist activity in vitro and show antiangiogenic capacity in vivo. Thus, as few as 8 monosaccharide units [as in LMW-K5(C)] are sufficient to confer to K5-N,OS(H) derivatives a full angiostatic capacity.

The minimal FGF2-binding sequence in heparan sulfate is a pentasaccharide that contains the disaccharide units IdoA2SO3–-GlcNSO3– or IdoA2SO3–-GlcNSO3–,6SO3–.38 K5 derivatives can be chemically and enzymatically modified to reproducible structures in which sulfated groups and GlcA/IdoA residues are distributed along the GAG chain in a statistically homogenous manner.18,39–41 Surface plasmon resonance analysis demonstrates that free K5-N,OS(H), IMW-K5, and all LMW-K5 derivatives ({approx}70% of their sequence represented by GlcA2,3SO3–-GlcNSO3–,6SO3– disaccharide units) compete with immobilized heparin for the binding to FGF2 with similar potency and only slightly less efficiently than free UFH or LMWH when GAG chain concentration was expressed on a weight basis. This is in keeping with the hypothesis that more FGF2 molecules bind to a single heparin chain and that the stoichiometry of FGF2/heparin complexes depends on the size of the GAG. A single UFH or LMWH chain binds 6 or 2 FGF2 molecules, respectively, both heparin types giving a heparin mass of 2300 per FGF2-binding site.42 Similarly, it is possible to hypothesize that LMW-K5 chains can bind 2 to 3 FGF2 molecules per complex and that longer IMW-K5 and K5-N,OS(H) chains will bind a proportionally higher number of growth factor molecules.

FGF2 interaction with nonsignaling HSPGs is required for the binding to FGFRs. FGFR occupancy will then lead to multiple biological responses in cultured endothelial cells and eventually to in vivo neovascularization.11 Similar to K5-N,OS(H) and IMW-K5, LMW-K5 derivatives abrogate FGF2-mediated attachment of FGFR1-expressing cells to neighboring HSPG-bearing cells, thus indicating their ability to prevent the formation of the HSPG/FGF2/FGFR ternary complex.23 Synthetic molecules and chemically modified heparins that interfere with HSPG/FGF2/FGFR interaction act as angiogenesis inhibitors (reviewed in Presta et al8). Accordingly, K5-N,OS(H) derivatives suppress neovascularization in the chick embryo CAM.

Similar to K5 derivatives, heparin binds FGF2 and prevents HSPG/FGF2/FGFR interaction and FGF2-driven endothelial cell proliferation in vitro. However, at variance with K5 derivatives, heparin does not affect endothelial cell sprouting in vitro and angiogenesis in vivo. This apparent discrepancy may be explained by the observation that K5 derivatives, but not heparin, also prevent the interaction of FGF2 with {alpha}vß3 integrin. {alpha}vß3 plays an important role in angiogenesis,35 and FGF2/{alpha}vß3 interaction is required for endothelial cell response to the growth factor.14–16 Also, numerous observations point to an intimate cross-talk between integrin-mediated intracellular signaling and angiogenic growth factor tyrosine kinase receptor activation.43 Accordingly, {alpha}vß3 represents a target for angiostatic compounds.44 Thus, the capacity of K5 derivatives to interfere with both HSPG/FGF2/FGFR and FGF2/{alpha}vß3 interactions results in a potent angiostatic activity.

K5 derivatives do not inhibit integrin-mediated endothelial cell adhesion to vitronectin (a prototypic {alpha}vß3 ligand) or fibronectin (a prototypic {alpha}5ß1 ligand), indicating that the observed FGF2/{alpha}vß3 antagonist activity is because of the capacity of these compounds to bind the growth factor rather than the integrin molecule. The characterization of the structural requirements for the FGF2/{alpha}vß3 antagonist activity of K5 derivatives deserves further investigation.

Both thrombotic and hemorrhagic complications have been reported in cancer patients undergoing antiangiogenic therapy (discussed in Daly et al45). The occurrence of these life-threatening complications suggests that the use of antiangiogenic compounds endowed with anticoagulant activity or in association with anticoagulants should be approached with caution. Relevant to this point, K5-N,OS(H) and its LMW derivatives are endowed with negligible anticoagulant activity (P.O. and G. Z., unpublished data, 2003). LMW-K5 compounds may therefore provide the basis for the design of novel LMW angiostatic compounds with therapeutic implications in angiogenesis-dependent diseases, including cancer.


*    Acknowledgments
 
This work was supported by grants from Ministero dell’ Istruzione, Università e Recerca (MIUR) (Centro di Eccellenza, Innovazione Diagnostica e Terapeutica [IDET], Firb 2001, Cofin 2002), Associazione Italiana per la Ricerca sul Cancro (AIRC), and Istituto Superiore di Sanitá (ISS; Oncotechnological Program) to M.P., and from MIUR (Cofin 2003) to M.R. and (Firb 2001) to D.R.

Received March 9, 2004; accepted October 7, 2004.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Roden L, Ananth S, Campbell P, Curenton T, Ekborg G, Manzella S, Pillion D, Meezan E. Heparin: an introduction. Adv Exp Med Biol. 1992; 313: 1–20.[Medline] [Order article via Infotrieve]
  2. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem. 2001; 57: 159–206.[Medline] [Order article via Infotrieve]
  3. Lindahl U, Lidholt K, Spillmann D, Kjellen L. More to "heparin" than anticoagulation. Thromb Res. 1994; 75: 1–32.[CrossRef][Medline] [Order article via Infotrieve]
  4. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer. 1994; 74: 38–45.[CrossRef][Medline] [Order article via Infotrieve]
  5. von Tempelhoff GF, Heilmann L. Antithrombotic therapy in gynecologic surgery and gynecologic oncology. Hematol Oncol Clin North Am. 2000; 14: 1151–1169, ix.
  6. Zacharski LR, Ornstein DL, Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost. 2000; 26 (suppl 1): 69–77.
  7. Engelberg H. Actions of heparin that may affect the malignant process. Cancer. 1999; 85: 257–272.[CrossRef][Medline] [Order article via Infotrieve]
  8. Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, Moroni E, Liekens S, Rusnati M. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des. 2003; 9: 553–566.[CrossRef][Medline] [Order article via Infotrieve]
  9. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol. 2000; 34: 185–194.[Medline] [Order article via Infotrieve]
  10. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front in Biosci. 1999; 4: D165–D177.Review.
  11. Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell. 1995; 83: 357–360.Review.[CrossRef][Medline] [Order article via Infotrieve]
  12. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000; 6: 743–750.[CrossRef][Medline] [Order article via Infotrieve]
  13. Coltrini D, Rusnati M, Zoppetti G, Oreste P, Grazioli G, Naggi A, Presta M. Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochem J. 1994; 303 (pt 2): 583–590.
  14. Tanghetti E, Ria R, Dell’Era P, Urbinati C, Rusnati M, Ennas MG, Presta M. Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene. 2002; 21: 3889–3897.[CrossRef][Medline] [Order article via Infotrieve]
  15. Rusnati M, Tanghetti E, Dell’Era P, Gualandris A, Presta M. {alpha}vß3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol Biol Cell. 1997; 8: 2449–2461.[Abstract/Free Full Text]
  16. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, Varner J, Liu M, Smith EM, Neustadt B, Presta M, Armstrong L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual {alpha}(v)ß3 and {alpha}(v)ß5 integrin receptor antagonist. Cancer Res. 2001; 61: 2232–2238.[Abstract/Free Full Text]
  17. Vann WF, Schmidt MA, Jann B, Jann K. The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin. Eur J Biochem. 1981; 116: 359–364.[Medline] [Order article via Infotrieve]
  18. Naggi A, Torri G, Casu B, Oreste P, Zoppetti G, Li JP, Lindahl U. Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide. Semin Thromb Hemost. 2001; 27: 437–443.[CrossRef][Medline] [Order article via Infotrieve]
  19. Razi N, Feyzi E, Bjork I, Naggi A, Casu B, Lindahl U. Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide. Biochem J. 1995; 309 (pt 2): 465–472.
  20. Oreste P, Zoppetti G. Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation. US patent application No. US 2002 062019; 2002.
  21. Borgenstrom M, Jalkanen M, Salmivirta M. Sulfated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling. J Biol Chem. 2003; 278: 49882–49889.[Abstract/Free Full Text]
  22. Vicenzi E, Gatti A, Ghezzi S, Oreste P, Zoppetti G, Poli G. Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. AIDS. 2003; 17: 177–181.[CrossRef][Medline] [Order article via Infotrieve]
  23. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem. 2001; 276: 37900–37908.[Abstract/Free Full Text]
  24. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992; 79: 1–17.[Free Full Text]
  25. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997; 337: 688–698.[Free Full Text]
  26. Esko JD. Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol. 1991; 3: 805–816.[CrossRef][Medline] [Order article via Infotrieve]
  27. Liekens S, Leali D, Neyts J, Esnouf R, Rusnati M, Dell’Era P, Maudgal PC, De Clercq E, Presta M. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol Pharmacol. 1999; 56: 204–213.[Abstract/Free Full Text]
  28. Sola F, Gualandris A, Belleri M, Giuliani R, Coltrini D, Bastaki M, Tosatti MP, Bonardi F, Vecchi A, Fioretti F, Ciomei M, Grandi M, Mantovani A, Presta M. Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice. Angiogenesis. 1997; 1: 102–116.[CrossRef][Medline] [Order article via Infotrieve]
  29. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest. 1990; 63: 115–122.[Medline] [Order article via Infotrieve]
  30. Thompson LD, Pantoliano MW, Springer BA. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry. 1994; 33: 3831–3840.[CrossRef][Medline] [Order article via Infotrieve]
  31. Li LY, Seddon AP. Fluorospectrometric analysis of heparin interaction with fibroblast growth factors. Growth Factors. 1994; 11: 1–7.[Medline] [Order article via Infotrieve]
  32. Richard C, Liuzzo JP, Moscatelli D. Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. J Biol Chem. 1995; 270: 24188–24196.[Abstract/Free Full Text]
  33. Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Molinari-Tosatti MP, Bonardi F, Parolini S, Albini A, Morbidelli L, Ziche M, Corallini A, Possati L, Vacca A, Ribatti D, Presta M. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ. 1996; 7: 147–160.[Abstract]
  34. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996; 12: 697–715.[CrossRef][Medline] [Order article via Infotrieve]
  35. Ruegg C, Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci. 2003; 60: 1135–1157.[Medline] [Order article via Infotrieve]
  36. Casu B, Guerrini M, Naggi A, Perez M, Torri G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry. 2002; 41: 10519–10528.[CrossRef][Medline] [Order article via Infotrieve]
  37. Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, Cassinelli G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem. 2004; 47: 838–848.[CrossRef][Medline] [Order article via Infotrieve]
  38. Maccarana M, Casu B, Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem. 1994; 269: 3903. Erratum.[Free Full Text]
  39. Casu B, Grazioli G, Hannesson H, Jan B, Jann K, Lindahl U, Naggi A, Oreste P, Razi N, Torri G, Tursi F, Zoppetti G. Biological active, heparan sulfate-like species by combined chemical and enzymic modification of the Escherichia coli polysaccharide K5. Carbohydr Lett. 1994; 1: 107–114.
  40. Kusche M, Hannesson HH, Lindahl U. Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzymic polymer-modification reactions. Biochem J. 1991; 275 (pt 1): 151–158.
  41. Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G, Oreste P, Tursi F, Zoppetti G, Lindahl U. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res. 1994; 263: 271–284.[CrossRef][Medline] [Order article via Infotrieve]
  42. Arakawa T, Wen J, Philo JS. Stoichiometry of heparin binding to basic fibroblast growth factor. Arch Biochem Biophys. 1994; 308: 267–273.[CrossRef][Medline] [Order article via Infotrieve]
  43. Eliceiri BP. Integrin and growth factor receptor crosstalk. Circ Res. 2001; 89: 1104–1110.[Abstract/Free Full Text]
  44. Kumar CC. Integrin {alpha} v ß 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003; 4: 123–131.[CrossRef][Medline] [Order article via Infotrieve]
  45. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst. 2003; 95: 1660–1673.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. Narita, J. Staub, J. Chien, K. Meyer, M. Bauer, A. Friedl, S. Ramakrishnan, and V. Shridhar
HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo.
Cancer Res., June 15, 2006; 66(12): 6025 - 6032.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
25/1/71    most recent
01.ATV.0000148863.24445.b4v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Presta, M.
Right arrow Articles by Ribatti, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Presta, M.
Right arrow Articles by Ribatti, D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Heparin
Right arrow Angiogenesis

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.